Cellectis extends its TAL technology intellectual property portfolio through the acquisition of two exclusive licenses from Iowa State University
Published on October 25, 2012
Paris, France, October 25th, 2012 - Cellectis (Alternext: ALCLS), the genome engineering specialist, announces that it has signed two exclusive license agreements with the Iowa State University that grant Cellectis the worldwide right to use inventions related to TAL effector-nucleases (TALENsTM) and monomeric TALENsTM.
These two exclusive licenses granted to Cellectis cover all uses of the TAL technologies in any field. TALENsTM are revolutionary new tools for genome engineering, which allow a more efficient and targeted ways for DNA recognition and cleavage, in any genome of any species. This technology has broad applications in genome engineering including fundamental genetic research, crop improvement, and treatment of human genetic diseases.
Cellectis has already integrated TAL effector nucleases into its DNA nuclease production platform. TAL effector nucleases are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest, in any species. Cellectis is able to produce TAL nucleases in around one week, providing customers with rapid access to custom-made products.
“Cellectis strengthens its leading position in the genome engineering arena” stated André Choulika, CEO of Cellectis. “Cellectis’ R&D teams are already applying these technologies for our programs and we are extending our offerings to a wider range of innovative first-in-class services and research reagents based on it”.